加拿大不列颠哥伦比亚省HPV疫苗接种十年后宫颈癌筛查女性高危HPV流行率
该研究在不列颠哥伦比亚省公开资助的学校HPV疫苗接种项目实施十年后,对宫颈癌筛查女性的高危HPV(hrHPV)流行率进行再评估。2017年8月至2018年3月收集3107份有效样本,结果显示总体hrHPV流行率2010/11年为12.2%(95%CI 11.3-13.3),2017/18年为12.0%(95%CI 10.9-13.2);疫苗合格年龄组(15-22岁)HPV16/18流行率呈下降迹象,但各hrHPV型别期间差异无统计学意义。
要点
- 总体hrHPV流行率十年间保持稳定,2010/11年12.2%,2017/18年12.0%。
- 15-22岁疫苗合格女性HPV16流行率从8.8%降至6.3%,HPV18从3.7%降至0%。
- 所有hrHPV型别在两个时期之间无统计学显著差异。
核心结论
- 不列颠哥伦比亚省宫颈癌筛查女性中总体hrHPV流行率十年间无显著变化,但疫苗合格年龄组HPV16/18流行率呈下降迹象。
研究设计与样本
- 2017年8月至2018年3月邀请1107名医生返还常规Pap筛查所用细胞刷至宫颈癌筛查实验室进行HPV检测,仅收集年龄或出生年份,共3107份样本纳入分析。
- 比较15-22岁(学校疫苗接种合格)与23岁以上(不合格)女性在2010/11和2017/18两个时期的HPV型别流行率。
主要发现
- 总体hrHPV流行率2010/11年为12.2%(95%CI 11.3-13.3),2017/18年为12.0%(95%CI 10.9-13.2)。
- 15-22岁组任何hrHPV流行率2010/11年为26.8%(95%CI 23.1-30.8),2017/18年为25.4%(95%CI 15.3-37.9)。
- 15-22岁组HPV16流行率2010/11年为8.8%(95%CI 6.5-11.5),2017/18年为6.3%(95%CI 1.8-15.5)。
- 15-22岁组HPV18流行率2010/11年为3.7%(95%CI 2.3-5.7),2017/18年为0%(95%CI 0.0-5.7)。
- 所有hrHPV型别在两个时期之间无统计学显著差异。
临床怎么用
- 在HPV疫苗接种十年后,应持续监测疫苗合格女性中HPV16/18流行率变化以评估免疫规划效果。
局限性
- 仅收集年龄或出生年份,缺乏其他人口学或行为学信息。
- 15-22岁组2017/18年样本量较小,导致置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: British Columbia (BC) introduced a publicly funded, school-based human papillomavirus (HPV) immunization program in 2008 with the quadrivalent vaccine. In 2010/2011, a baseline evaluation of HPV prevalence was conducted among women undergoing cervical cancer screening. After 10 years of publicly funded HPV vaccination, HPV-type prevalence was re-evaluated. METHODS: From August 2017 to March 2018, 1107 physicians were invited to return cytobrushes used during routine Pap screening to the Cervical Cancer Screening Laboratory for HPV testing. Only age or year of birth was collected. Specimens were screened for high-risk HPV (hrHPV) and positive samples were genotyped. HPV type prevalence was compared for females 15-22 yrs (those eligible for the school-based vaccination) and 23+ yrs (ineligible for school-based vaccination) for the 2010/2011 and the 2017/2018 data. RESULTS: There were 3309 valid samples received for testing; of these, 3107 were included in the analysis. The overall hrHPV prevalence was 12.2% (95% CI 11.3-13.3) in 2010/11, and 12.0% (95% CI 10.9-13.2) in 2017/18. For the 15-22 age group, the prevalence for any hrHPV was 26.8% (95% CI 23.1-30.8) in 2010/11 and 25.4% (95% CI 15.3-37.9) in 2017/18. For those aged 15-22, HPV16 prevalence in 2010/11 was 8.8% (95% CI 6.5-11.5) and in 2017/18 was 6.3% (95% CI 1.8-15.5), with corresponding figures for HPV18 3.7% (95% CI 2.3-5.7) and 0% (95% CI 0.0-5.7), respectively. For all hrHPV types, there were no statistically significant differences between the 2010/11 and 2017/18 periods. CONCLUSIONS: This study illustrates the prevalence of hrHPV in BC over time in women undergoing cervical cancer screening, where an indication of a decline in HPV16/18 is seen in vaccine eligible women.
引用
- Litwin C, Smith L, Donken R, et al. High-risk HPV prevalence among women undergoing cervical cancer screening: Findings a decade after HPV vaccine implementation in British Columbia, Canada. Vaccine. 2021. PMID: 34344555. doi:10.1016/j.vaccine.2021.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。